Link address : https://www.prnewswire.com/news-releases/sillajen-announces-first-patient-enrolled-in-part-2-of-renal-cell-carcinoma-trial-with-pexa-vec-in-combination-with-regenerons-libtayo-cemiplimab-rwlc-300862838.html
Targeting, Attacking, and Eradicating Cancers®
